Qlucore (QCORE) Q1 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 25/26 earnings summary
24 Sep, 2025Executive summary
Net sales for the first quarter were SEK 811k, a 52% decrease year-over-year due to a major customer not renewing licenses after internal cost cuts and reorganization.
Operating result (EBIT) improved to SEK -6,552k from SEK -7,620k year-over-year.
Net result for the period was SEK -6,619k, compared to SEK -7,529k in the prior year.
A rights issue post-period injected SEK 14.5 million in liquidity, with a significant dilution effect.
Focus during the period was on securing financing, expanding market presence, and implementing a cost-saving program exceeding 25%.
Financial highlights
Net sales dropped 51.6% year-over-year to SEK 811k.
Operating result (EBIT) margin improved to -193.6% from -278.3% year-over-year.
EBITDA for the quarter was SEK -4,382k, up from SEK -6,470k last year.
Cash flow from operating activities was SEK 1,926k, down from SEK 2,480k.
Net cash flow was SEK 774k, compared to SEK -209k last year.
Outlook and guidance
No formal market outlook or business performance forecast is provided.
Cost-saving measures, including personnel reductions, are expected to take full effect in November.
The liquidity injection from the rights issue is expected to ensure stable operations.
Latest events from Qlucore
- Sales declined sharply and losses deepened, but new cancer diagnostics were launched.QCORE
Q4 25/2628 May 2026 - Sales fell sharply and losses persisted, but cash flow improved after a rights issue.QCORE
Q3 25/2626 Feb 2026 - Q2 saw lower sales, major write-offs, cost cuts, and improved liquidity from a rights issue.QCORE
Q2 25/2627 Nov 2025 - Sales fell sharply year-over-year, but Q4 losses narrowed and first Diagnostics sale completed.QCORE
Q4 24/2518 Jun 2025 - Regulatory milestones achieved, but sales and profitability declined significantly year-over-year.QCORE
Q2 24/2513 Jun 2025 - Qlucore's Q1 loss widened as sales fell, but EU funding boosted cash flow and supported diagnostics R&D.QCORE
Q1 24/2513 Jun 2025 - Sales fell sharply and liquidity is critical despite Diagnostics BCP-ALL 1.0 launch.QCORE
Q3 24/255 Jun 2025